Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

Alithea Genomics Launches MERCURIUS™ Full-Length DRUG-seq Technology for Large-Scale RNA Sequencing

NextEdge Admin

07 Dec 2024

2 min 10 sec

RNA Sequencing,drug development,biomarker,research

Alithea Genomics, a leader in RNA sequencing and transcriptomics, has unveiled MERCURIUS™ Full-Length DRUG-seq, an innovative library preparation technology that combines massive sample multiplexing, an extraction-free workflow, and full transcript coverage. Designed for 96- and 384-well plate formats, the technology can process up to 384 RNA-seq libraries in a single tube without RNA isolation.

This breakthrough enables scientists to detect a broader range of biologically meaningful features, including diverse transcripts, isoforms, and splicing variants, compared to 3’ mRNA-seq methods. “Full-Length DRUG-seq allows large-scale compound screening based on full-length RNA sequencing, opening new avenues in drug discovery targeting specific gene isoforms and splicing,” said Riccardo Dainese, PhD, CEO of Alithea Genomics.

MERCURIUS™ Full-Length DRUG-seq offers Illumina-compatible libraries, providing full-length transcript coverage and detecting over 40,000 transcripts at just 4M reads/sample. The method achieves results comparable to non-multiplexed gold-standard techniques while minimizing time and costs.

This launch reflects Alithea’s commitment to delivering advanced, time-efficient solutions leveraging multiplexing and extraction-free workflows for various sample types. The company plans further product launches through 2025.

Founded in 2020 at EPFL, Lausanne, Switzerland, Alithea Genomics specializes in massively multiplexed RNA library preparation, including BRB-seq (Bulk RNA Barcoding and Sequencing), which reduces costs and labor for RNA sequencing. Alithea’s technologies enable scalable biomarker discovery and data generation, accelerating drug development and research.